Nasdaq GlobeNewswire

Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio

Del

--  Facility to support development of advanced gene and cell therapies for treatment of life-threatening rare diseases

  --  Leaders from local government, life sciences and medical technology to join on October 4 for dedication of first anticipated gene and cell therapy production center in Ohio

CLEVELAND, Oct. 04, 2017 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today the ground-breaking of the first anticipated commercial gene therapy manufacturing facility in Ohio. The Cleveland-based facility, named The Elisa Linton Center for Rare Disease Therapies, will have the capacity to produce advanced gene and cell therapies to treat serious and debilitating rare diseases. The dedication and ground-breaking ceremony is being held today, October 4, 2017.  

"We are very excited to announce the creation of The Elisa Linton Center for Rare Disease Therapies, which will be a global resource for production of gene therapies with the potential to bring new treatments to rare disease patients around the world," said Timothy J. Miller, Ph.D., President and CEO of Abeona Therapeutics. "It is especially fitting that this center is named for Elisa Linton, who was born with Sanfilippo syndrome, a rare terminal disease. The memory of Elisa and courage of her family continue to be a great inspiration to all members of the rare disease community."

The Elisa Linton Center for Rare Disease Therapies will initially be used to produce ABO-101 and ABO-102, investigational gene therapies currently in development at Abeona for the treatment of patients with Sanfilippo syndrome, and EB-101, an investigational autologous cell therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare and devastating skin disorder. The Center will also house Abeona's expanded viral-vector lab, which will develop and produce unique and proprietary vectors used for the delivery of gene therapies. The 6,000 square foot Center will be built-out and validated over the next 12 months.

"The Epidermolysis Bullosa Medical Research Foundation, along with the EB Research Partnership, is a longtime supporter of research that may help patients living with EB including the development of EB-101. The development of EB-101 is a great example of the progress we are making in EB research today," said Paul Joseph, Chief Financial Officer of the Epidermolysis Bullosa Medical Research Foundation. "We are very pleased to support Abeona taking steps to establish a world-class gene therapy production facility that will bring new hope to people living with EB and other serious diseases and conditions."

Several leaders from local government and life sciences are scheduled to attend the dedication ceremony of the Center, including representatives from United States Senator Sherrod Brown's office, Case Western Reserve University, BioEnterprise, MidTown Cleveland, Inc. and JumpStart Inc.

"Today's groundbreaking celebration represents another successful investment in Ohio innovation and manufacturing," said Senator Brown. "It's exciting to see investments in gene therapy treatments for rare diseases happening right here in Cleveland, helping to cement Ohio's leadership in the healthcare and technology industries. Today's ceremony is another step forward for the health of rare disease patients and for the strength of the region's economy."

"We applaud Abeona's decision to open a state-of-the-art gene therapy facility in Cleveland's Health-Tech Corridor," said Aram Nerpouni, President and CEO of BioEnterprise. "The Cleveland bioscience industry has grown remarkably in the past decade and Abeona's investment is a potent example of our region's momentum. We look forward to our ongoing relationship with Abeona and other emerging bioscience companies that continue to grow and strengthen our local economy."

About EB Medical Research Foundation: As the leader in research funding, the Epidermolysis Bullosa Medical Research Foundation is an all-volunteer, non-profit 501(c) Foundation dedicated to funding research for Epidermolysis Bullosa to determine its causes, develop successful treatments, and ultimately find a cure. EB is a rare, debilitating and often fatal genetic disorder which causes painful scarring and blistering of the skin and internal organs. Our continued goal is to raise awareness through special events, the media and fundraising programs. www.ebmrf.org

About BioEnterprise: BioEnterprise is a business formation, recruitment, and acceleration effort designed to support the growth of bioscience companies. Located in Cleveland, BioEnterprise provides management counsel and support services to health IT, medical device, and biopharmaceutical companies. BioEnterprise founders are Case Western Reserve University, Cleveland Clinic, and University Hospitals. Additional technology partners include the NASA Glenn Research Center, Cleveland State University, and BioOhio. The initiative comprises the collective activities of BioEnterprise and its partners' commercialization offices: The Case Office of Technology Transfer, Cleveland Clinic Innovations, and University Hospitals Cleveland - Center for Clinical Research. The combined efforts of these groups has created, recruited, and accelerated more than 300 companies in 15 years. For more information: www.BioEnterprise.com.

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).  Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a proprietary vector platform, AIM(TM), for next generation product candidates.  For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212) 786-6212
csilverstein@abeonatherapeutics.com

Media Contact: 
Lynn Granito
Berry & Company Public Relations  
+1 (212) 253-8881  
lgranito@berrypr.com

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, that patients will continue to be identified, enrolled, treated and monitored in the EB-101 clinical trial, and that studies will continue to indicate that EB-101 is well-tolerated and may offer significant improvements in wound healing; the addition of two additional global clinical sites will accelerate our ability to enroll and evaluate ABO-102 as a potential treatment for patients with Sanfilippo syndrome type A, or MPS IIIA.  Such statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to secure licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; our belief that initial signals of biopotency and clinical activity, which suggest that ABO-102 successfully reached target tissues throughout the body, including the central nervous system and the increased reductions in CNS GAG support our approach for intravenous delivery for subjects with Sanfilippo syndromes, and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

FOUR IN FIVE EXECUTIVES AGREE AGILITY IS MOST IMPORTANT CHARACTERISTIC OF A SUCCESSFUL ORGANIZATION18.9.2018 16:03Pressemelding

New research by Forbes Insights and sponsored by Scrum Alliance brings light to the “elusive” Agile enterprise Denver Colorado, Sept. 18, 2018 (GLOBE NEWSWIRE) -- PRESS RELEASE FOR IMMEDIATE RELEASE: MEDIA CONTACT: September 18, 2018 Heather Leigh, Public Relations Director 720-443-7314,hleigh@scrumalliance.org www.scrumalliance.org SEPTEMBER 18, 2018 – DENVER, CO – A new report by Forbes Insights finds 81 percent of respondents agree on the critical importance of agility when it comes to leading a successful organization. The report, “The Elusive Agile Enterprise,” was sponsored by Scrum Alliance, a Scrum certifying body and the largest professional association of Agile practitioners worldwide. In preparing the report, the Forbes Insights team surveyed more than 1,000 C-level executives worldwide, and also conducted one-on-one interviews with leaders of select “champion” organizations, including GEHealthcare, J. Walter Thompson Company, Nokia, Team WIKISPEED, Toyota Connected and Unis

Cloudian Joins iRODS Consortium18.9.2018 15:00Pressemelding

HyperStore Enterprise Object Storage Validated with iRODS Platform SAN MATEO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Cloudian today announced the company has joined the iRODS Consortium, the foundation that leads development and support of the integrated Rule-Oriented Data System (iRODS). Testing for HyperStore enterprise object storage with iRODS is complete, and users may now deploy the combined solution where local workflows require cost-effective, exabyte-scalable storage and ease of integration. iRODS is free open source software for data discovery, workflow automation, secure collaboration and data virtualization used by research and business organizations around the globe. Easily deployed in an existing infrastructure, iRODS creates a unified namespace and a metadata catalog of all the data and users within the storage environment. With the iRODS rule engine framework, users can completely automate an organization’s data management policy. “We’re thrilled to be working with

Harbert European Growth Capital Announces Final Close18.9.2018 14:35Pressemelding

LONDON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Harbert European Growth Capital (“HEGCF”), is pleased to announce the final close of its second fund (“Fund II”) at €215 million, a substantial increase over Harbert European Growth Capital Fund I (“Fund I”). HEGCF, which provides debt capital to fund growth opportunities across technology, life science and other innovative sectors attracted significant institutional capital, as well as numerous family office investors. “We are grateful for the support and trust that our existing and new investors have placed in us,” said David Bateman, Senior Managing Director and co-head of HEGCF. “The market opportunity remains strong with many companies across Europe seeking expansion funding of various forms,” notes Johan Kampe, Senior Managing Director and co-head of HEGCF. It has been a busy start with Fund II already having closed investments in 21 new companies since the first close in summer 2017. HECGF also continues to have follow on investing acti

Teledyne DALSA expands its area camera series with the industry’s first 5 Gigabit, GigE Vision models18.9.2018 14:30Pressemelding

Eight new Genie Nano cameras deliver fast, high-resolution inspection for existing GigE Vision machine vision systems WATERLOO, Ontario, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Teledyne DALSA, a Teledyne Technologies company and global leader in machine vision technology, is pleased to introduce its newest Genie Nano cameras with eight new monochrome and color models built around the industry’s best performing SONY ® image sensors. These industry-first 5-Gigabit GigE Vision cameras feature resolutions from 3.2Mpixels to 12Mpixels with more models to follow before the end of the year – including a 5Mpixel Polarized model. Engineered for imaging applications that require high-speed data transfer, these new Nano models are an easy replacement for cameras built into current vision systems that rely on the existing GigE vision interface standard. These new Genie Nano models feature the brand new 5GBASE-T link speed. IEEE 802.3bz-2016 is the expanded standard for Ethernet over twisted pair copper

Father’s personal experience drives hospitals to improve patient communication18.9.2018 14:00Pressemelding

CareCircle fills gap after CarePages closure leaves hospitals in a bind GRAND RAPIDS, Mich., Sept. 18, 2018 (GLOBE NEWSWIRE) -- After experiencing the challenges that come with communicating with friends and family from during his daughter's chemotherapy treatment for a rare disease, Nathan Loding, 34, of Grand Rapids thought there had to be a better way to keep friends and family updated on his daughter’s condition and get the support their family needed. Thanks to his livelihood as a software developer at Grand Rapids-based global business technology firm OST, he quickly turned his idea into reality. The result is CareCircle (www.carecircle.com), a secure website that allows patients to safely provide updates on their health and share private information with a select audience. The site launched Sept. 1 and has already been piloted by one of the nation’s largest health care systems. The platform is wholly-owned and operated by OST. CareCircle’s launch is very timely, as popular patie

Talend Supports La Mutuelle Générale to Power its AWS Cloud Data Lake18.9.2018 14:00Pressemelding

Health Insurance Company Accelerates the Implementation of New Services and Strengthen Business Applications REDWOOD CITY, Calif. & SURESNES, France, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud data integration solutions, today announced that La Mutuelle Générale, a leading provider of insurance solutions for businesses and individuals, has chosen Talend Cloud Platform to support the company in their project to build an Amazon Web Services (AWS)-based cloud data lake to serve as the foundation of all their data initiatives. With Talend, La Mutuelle Générale provides self-service data access for its data scientists to improve customer relations and offer innovative services. "As is the case in many industries, the insurance sector is in the midst of a transformation from a technical to a service industry. As part of our global business approach, we place digitalization, data and innovation at the heart of our strategy and customer satisfaction," sa

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom